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ORIGINAL RESEARCH
Role of Endothelial Nitric Oxide Synthase 
in Isoflurane Conditioning-Induced 
Neurovascular Protection in Subarachnoid 
Hemorrhage
Umeshkumar Athiraman , MD; Keshav Jayaraman, BA; Meizi Liu, MD; Tusar Giri, MD, PhD; Jane Yuan , BA; 
Gregory J. Zipfel, MD
BACKGROUND: Delayed cerebral ischemia remains a common and profound risk factor for poor outcome after subarachnoid 
hemorrhage (SAH). The aim of our current study is to define the role of endothelial nitric oxide synthase (eNOS) in isoflurane 
conditioning-induced neurovascular protection after SAH.
METHODS AND RESULTS: Ten- to 14-week-old male wild-type mice (C57BL/6) as controls and eNOS knockout male mice 
(strain # 002684) were obtained for the study. Animals underwent either sham surgery, SAH surgery, or SAH with isoflurane 
conditioning. Anesthetic post conditioning was performed with isoflurane 2% for 1 hour, 1 hour after SAH. Normothermia 
was maintained with the homeothermic blanket. In a separate cohort, nitric oxide synthase was inhibited by a pan nitric oxide 
synthase inhibitor, L-nitroarginine methyl ester. Vasospasm measurement was assessed 72 hours after SAH and neurologi-
cal function was assessed daily. Isoflurane-induced changes in the eNOS protein expression were measured. eNOS protein 
expression was significantly increased by isoflurane conditioning in naïve mice as well as mice subjected to SAH. Vasospasm 
of the middle cerebral artery and neurological deficits were evident following SAH versus sham surgery, both in wild-type mice 
and eNOS knockout mice. Isoflurane conditioning attenuated vasospasm and neurological deficits in wild-type mice. This 
delayed cerebral ischemia protection was lost in L-nitroarginine methyl ester -administered mice and eNOS knockout mice.
CONCLUSIONS: Our data indicate isoflurane conditioning provides robust protection against SAH-induced vasospasm and neu-
rological deficits, and that this delayed cerebral ischemia protection is critically mediated via isoflurane-induced augmentation 
of eNOS.
Key Words: aneurysmal subarachnoid hemorrhage ■ delayed cerebral ischemia ■ endothelial nitric oxide synthase  
■ isoflurane conditioning
Despite an improved understanding of vasospasm pathophysiology and advances in medical and endovascular techniques for rescue therapy, 
cerebral vasospasm and the delayed cerebral isch-
emia (DCI) that it produces remains a common and 
profound risk factor for poor outcome after aneurys-
mal subarachnoid hemorrhage (SAH).1 Though many 
strategies to prevent DCI have been explored over 
the years, none have proven efficacious. This is likely 
attributable to targeting individual elements of what 
has proven to be a multifactorial process. Conditioning 
is a therapeutic strategy that leverages endogenous 
protective mechanisms to exert powerful and remark-
ably pleiotropic protective effects against injury to all 
major cell types of the central nervous system includ-
ing neurons, glia, and vascular cells.2 We previously 
showed that structurally distinct conditioning agents 
(hypoxia3 and the inhalational anesthetic, isoflurane4) 
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provide strong protection against SAH-induced DCI in 
mice endovascular perforation model. In the case of 
hypoxic conditioning, endothelial nitic oxide synthase 
(eNOS) was implicated in the afforded DCI protection.3 
In the case of isoflurane conditioning, previous inves-
tigators have demonstrated that eNOS is likely a key 
downstream effector for the anesthetic-based organ 
protection,5 though none have examined its impact on 
SAH-induced brain injury. The aim of our current study 
is to evaluate the role of eNOS in isoflurane-induced 
protection against vasospasm and neurological defi-
cits following SAH. Our hypothesis is that isoflurane 
conditioning induces robust protection against DCI 
after SAH, and that eNOS is the key molecular inducer 
of this neurovascular protection.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reasonable 
request. All studies were approved by the animal stud-
ies committee at Washington University in Saint Louis. 
Ten- to 14-week-old male wild-type mice (C57BL/6J) 
as controls and eNOS knockout male mice (strain # 
002684, B6.129P2-Nos3tm1Unc/J with C57BL/6J 
genetic background) were obtained from Jackson 
Laboratories (Bar Harbor, ME). Animals underwent 
either sham surgery, SAH surgery or SAH with isoflu-
rane conditioning. SAH was induced by endovascular 
perforation model as explained previously.4 Briefly, a 
5-0 blunted nylon suture was advanced through left 
external carotid artery into internal carotid artery and 
advanced distally until the resistance is felt at its bifur-
cation into anterior cerebral artery and middle cerebral 
artery. The suture was advanced to cause perforation 
in the SAH group and the suture was removed without 
perforation in the sham group. Anesthetic conditioning 
was performed with isoflurane 2% for 1 hour beginning 
1 hour after induction of SAH. Briefly, spontaneously 
breathing mice were placed in the anesthetic induction 
chamber and perfused with isoflurane 2% with room 
air for 1 hour. The sham group were placed in the same 
induction chamber but exposed only to room air for 
1  hour. Isoflurane concentration in the anesthetic in-
duction chamber was measured by an anesthetic gas 
analyzer. (Datex Ohmeda, Capnomac Ultima, USA) 
Normothermia at 37°C was maintained with the ho-
meothermic blanket. To examine the role of nitric oxide 
synthase (NOS) in isoflurane conditioning induced neu-
rovascular protection, a separate wild-type cohort was 
injected with pan NOS inhibitor, L-nitroarginine methyl 
ester (L-NAME) 20 mg/kg intraperitoneally 1 hour be-
fore SAH induction and every day thereafter until the 
animal was euthanized. SAH -induced large artery 
vasospasm was measured at 72 hours after SAH by 
a pressure controlled cerebrovascular casting with 
ROX-SE (5-(and-6)-Carboxy-X-rhodamine, succinimi-
dyl ester) technique.6 The narrowest diameter within 
the first 1000 um in the middle cerebral artery vessel 
was measured to evaluate for vasospasm using a fluo-
rescent microscope using a charged-coupled device 
(CCD) camera (Cool SNAP EZ, Photometrics, Tucson, 
AZ) and MetaMorph software (Universal Imaging, West 
Chester, PA). Neurological outcome was measured at 
baseline and for the next 3  days as explained previ-
ously.3,4 Briefly, it was measured by a motor score 
(0–12) that evaluated spontaneous activity, symmetry 
of limb movements, climbing, balance, and coordi-
nation and sensory score (4–12) that evaluated body 
proprioception, vibrissae, visual and tactile response. 
All experiments were randomized and blinded such 
that the investigator assessing the neurological out-
come and vasospasm is blinded to the treatment 
group. Isoflurane-induced changes in the eNOS pro-
tein expression with and without SAH were measured 
via Western blot technique as explained previously.3 
Briefly, brains harvested at different time points after 
isoflurane exposure with and without SAH surgery 
were lysed in a radioimmunoprecipitation assay buffer 
Nonstandard Abbreviations and Acronyms
DCI delayed cerebral ischemia
eNOS endothelial nitric oxide synthase
L-NAME L-nitroarginine methyl ester
CLINICAL PERSPECTIVE
What Is New?
• We examined the role of isoflurane conditioning 
and the endothelial nitric oxide synthase (eNOS) 
pathway in subarachnoid hemorrhage (SAH), a 
pathophysiologically unique and more severe 
form of stroke, that has not been previously 
examined.
• Our data suggests that isoflurane condition-
ing provides strong protection against SAH-
induced delayed cerebral ischemia and that this 
protection is causally mediated through eNOS.
What Are the Clinical Implications?
• Our findings lend biological relevance to the ob-
servation that isoflurane conditioning provides 
robust neurovascular protection in the setting of 
SAH, and has significant translational potential 
given that isoflurane is already approved by the 
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containing protease/phosphatase inhibitor cocktail. 
Equal amounts of protein (30 μg) were loaded and sep-
arated by 10% to 15% SDS-PAGE gel electrophoresis 
and then transferred to polyvinylidene difluoride mem-
brane. The membrane was blocked by 5% milk in 1X 
Tris-Buffered Saline, 0.1% Tween detergent for 1 hour 
at room temperature and was incubated overnight at 
4°C with rabbit anti-eNOS primary antibody (1:1000, 
Cell signaling Technology) and rabbit anti-B actin anti-
body (1:1000, Cell signaling Technology) in 5% bovine 
serum albumin. Subsequently, the blot was incubated 
with anti-rabbit horseradish peroxidase-conjugated 
secondary antibody (1:1000, Cell Signaling technology) 
at room temperature for 1 hour. The protein bands were 
visualized using an enhanced chemiluminescence kit 
(BioRad) and quantified by ImageJ.
Statistical Analysis
Data are represented as the mean±SEM. Large artery 
vasospasm and neurological outcome were analyzed 
by ANOVA and 2-way repeated measures ANOVA fol-
lowed by Newman Keuls multiple comparison test. 
Western blot data were analyzed by a t test and 
ANOVA followed by Newman Keuls multiple compari-
son test. Statistical significance was set at P<0.05.
RESULTS
eNOS Protein Expression After Isoflurane 
Conditioning With and Without SAH
eNOS protein expression was measured at different 
time points after single time exposure to 2% isoflurane 
for 1 hour. Isoflurane exposure significantly increased 
eNOS protein expression at 12, 36, 48, and 72 hours 
(P<0.05) (Figure  1A and 1B). In a separate cohort of 
mice that underwent SAH followed by isoflurane con-
ditioning (isoflurane 2% for 1 hour, 1 hour after SAH), 
eNOS protein expression was significantly increased 
24 hours after SAH (P<0.05, Figure 1C).
Isoflurane Conditioning Attenuates 
Vasospasm and Improves Neurological 
Outcome After SAH in Wild-Type Mice
Out of a total of 78 wild-type mice used in the experi-
ment, 4 animals (5%) died in SAH group and none died 
Figure 1. Isoflurane and endothelial nitric oxide synthase 
protein expression with and without SAH.
A, Wild-type mice were exposed to air or 2% isoflurane for 1 hour 
and cortical tissue harvested immediately and at 12, 36, 48, and 
72  hours after isoflurane exposure were subjected to Western 
blot. Data indicate mean±SEM. *P<0.05, **P<0.01 vs control 
(no isoflurane) by t test, n=4 mice per group. B, Representative 
immunoblot images. C, Wild-type mice underwent sham or SAH 
surgery and exposed to isoflurane 2% for 1 hour after 1-hour 
post-SAH. Cortical tissue harvested at 24  hours post-surgery 
were subjected to Western blot. Data indicate mean±SEM. 
*P<0.05 sham vs SAH-post-conditioning, *P<0.05 SAH vs 
SAH-post-conditioning by ANOVA followed by Newman-Keuls 
multiple comparison test (sham, n=9; SAH, n=9; SAH+Isoflurane, 
n=14). eNOS indicates endothelial nitric oxide synthase; postC, 
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in sham group. Animals subjected to surgery were 
found to have SAH at the time of animal euthanizing 
and none in sham group were noted to have SAH. 
Significant large artery vasospasm and neurological 
deficits were noted in mice subjected to SAH (middle 
cerebral artery diameter—63±17  μm) as compared 
Figure 2. Isoflurane conditioning attenuates SAH-induced vasospasm in wild-type mice.
A, Mice underwent sham or SAH surgery and exposed to isoflurane 2% for 1 hour after 1-hour 
post-SAH. On post-surgery day 3, mice were perfused with ROX-SE staining and vessel diameter 
in the proximal middle cerebral artery ipsilateral to suture perforation was measured. Data indicate 
mean±SEM. B, Representative images of 5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester 
casted vessels. Arrow mark represents the middle cerebral artery vessel. Scale bar=500  μm. 
C, Neuroscore was assessed daily and until 3 days after SAH. Data indicate mean±SEM. MCA 
indicates middle cerebral artery; postC, post-conditioning; ROX-SE, 5-(and-6)-Carboxy-X-
rhodamine, succinimidyl ester; SAH, subarachnoid hemorrhage; and WT, wild type. *P<0.05 
sham vs SAH, **P<0.01 SAH vs SAH-post-conditioning, by ANOVA and Newman-Keuls multiple 
comparison test, #P<0.05 SAH-post-conditioning vs SAH by 2-way repeated measures ANOVA 
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with sham surgery (91±31  μm) (P<0.05, Figure  2A 
and 2C). Isoflurane conditioning was found to provide 
strong protection against vasospasm (90±26 μm) and 
led to an improvement in neurological scores after SAH 
(P<0.05, Figure 2A through 2C).
L-NAME Administration Blocks Isoflurane-
Induced Neurovascular Protection Against 
SAH
Next, we sought to determine if NOS is a critical 
mediator of isoflurane induced neurovascular pro-
tection against SAH. Administration of the pan NOS 
inhibitor, L-NAME, eliminated the isoflurane pro-
tection afforded against SAH-induced vasospasm 
and neurological deficits in wild-type mice (P<0.05, 
Figure 3A and 3B).
Isoflurane-Induced Neurovascular Protection 
Against SAH is Lost in eNOS Null Mice
Out of 67 eNOS-null (eNOS−/−) mice used in the experi-
ment, 1 animal (1%) died in the SAH group and none 
died in sham group. All the animals subjected to surgery 
were found to have SAH at the time of animal euthaniz-
ing, and none in sham group were noted to have SAH. 
To directly implicate the role of eNOS in the isoflurane-
induced neurovascular protection in SAH, eNOS-null 
(eNOS−/−) mice were examined. Vasospasm and neu-
rological deficits were seen in eNOS−/− mice subjected 
to SAH (middle cerebral artery diameter—65±22 μm) 
as compared with sham surgery (86±27 μm) (P<0.05, 
Figure  3C and 3E), which is consistent with our past 
findings.3 In contradistinction to the impact of isoflu-
rane conditioning on SAH-induced vasospasm and 
Figure 3. Nitric oxide synthase inhibition blocks isoflurane conditioning-induced neurovascular protection against SAH-
induced delayed cerebral ischemia.
A and B, Wild-type mice underwent SAH or sham surgery followed 1 hour later by exposure to 2% isoflurane or room air for 1 hour. 
L-nitroarginine methyl ester 20 mg/kg was administered intraperitoneally before the surgery and every day after until the neurovascular 
assessment. Vasospasm (A) was assessed on day 3. Neuroscore was assessed daily (B). Data indicate mean±SEM. A, *P<0.05 
vs sham, (B) *P<0.05 vs sham by ANOVA and 2-way repeated measures ANOVA followed by Newman-Keuls multiple comparison 
test. C and E, Endothelial nitric oxide synthase knockout mice underwent SAH or sham surgery followed 1 hour later by exposure 
to 2% isoflurane or room air for 1 hour. Vasospasm (C) was assessed on day 3. Neuroscore was assessed daily (D). Data indicate 
mean±SEM. C, *P<0.05 sham vs SAH, *P<0.05 sham vs SAH-post-conditioning by ANOVA and Newman-Keuls multiple comparison 
test. D, Data indicate mean±SEM. *P<0.05 vs sham; #P<0.05 vs sham by 2-way repeated measures ANOVA followed by Newman-
Keuls multiple comparison test. 3D: Representative images of 5-(and-6)-Carboxy-X-rhodamine, succinimidyl ester casted vessels. 
Arrow mark represents the middle cerebral artery vessel. Scale bar=500 μm. eNOS indicates endothelial nitric oxide synthase; ISO, 
isoflurane; KO, knockout mice; L-NAME, L-nitroarginine methyl ester; MCA, middle cerebral artery; NOS, nitric oxide synthase; postC, 
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neurological deficits in wild-type mice, exposure to iso-
flurane conditioning did not provide protection against 
SAH-induced vasospasm (70±25 μm) or neurological 
deficits in eNOS−/− mice (P<0.05, Figure 3C through 3E).
DISCUSSION
The main findings of our study are as follows: (1) A 
single exposure to 2% isoflurane for 1 hour increased 
eNOS protein expression in naïve and SAH animals 
at clinically relevant timepoints; (2) A single exposure 
to 2% isoflurane for 1 hour initiated 1 hour after in-
duction of SAH provided strong protection against 
large artery vasospasm and neurological deficits 
(consistent with our prior findings; Milner et al4); (3) 
Pharmacological inhibition of NOS blocked isoflu-
rane-induced neurovascular protection in SAH; and 
(4) Global genetic knockout of eNOS blocked iso-
flurane-induced neurovascular protection in SAH. In 
total, these findings indicate eNOS is a critical media-
tor of the neurovascular protection afforded by isoflu-
rane conditioning in SAH.
Nitric oxide is a potent vasodilator, and reduced 
nitric oxide is strongly implicated in DCI.7 eNOS—1 
of the 3 known isoforms of NOS—is constitutively 
expressed in endothelial cells throughout the body 
including the central nervous system. It plays a key 
role in the mediation of endothelial cell-dependent 
vasodilation.8 While the effect of SAH on eNOS ex-
pression is controversial (some see no change9; oth-
ers see an increase10 or a decrease11), the concept 
that eNOS upregulation is beneficial for DCI is widely 
accepted.9,11 In the case of hypoxic conditioning for 
SAH, eNOS has been strongly implicated as a key 
mediator of the DCI protection afforded by this con-
ditioning strategy.3 In the case of isoflurane condi-
tioning, previous studies have implicated eNOS as a 
critical mediator for isoflurane induced-cardiac pro-
tection5; however, the role of eNOS in isoflurane con-
ditioning-induced protection of the central nervous 
system has yet to be examined.
Evidence indicates that multiple anesthetics sub-
stantially augment expression levels of eNOS and 
enhance the production of nitric oxide throughout the 
body.12 In the central nervous system, inhalational an-
esthetics have been shown to markedly increase pro-
duction of nitric oxide—a response that was blocked 
by administration of the pan-NOS inhibitor, Nw-nitro-l-
arginine.13 These findings are consistent with our re-
sults where we show isoflurane increases expression 
of eNOS in the presence and absence of SAH, and 
that both pharmacologic inhibition of NOS as well as 
genetic inhibition of eNOS block the neurovascular 
protection afforded by isoflurane conditioning in SAH. 
These data strongly suggest eNOS and nitric oxide 
are key downstream effectors by which isoflurane 
conditioning induces robust protection against SAH-
induced DCI. Though others have suggested that the 
neuronal NOS plays a role in isoflurane-induced ce-
rebral hyperemia,14 the impact of the endothelial NOS 
(eNOS) in isoflurane-induced protection against acute 
brain injury (including SAH) has not been previously 
elucidated. The results of the present study are there-
fore novel and impactful. When coupled with our pre-
vious finding that isoflurane conditioning-induced DCI 
protection in SAH is dependent on endothelial cell-de-
rived hypoxia inducible factor-1 alpha (a transcription 
factor known to regulate eNOS expression15), results 
from the present study suggest isoflurane conditioning 
may be inducing a multistep cascade that ultimately 
leads to the observed DCI and neurological protection.
Interestingly, we noted that L-NAME adminis-
tration in SAH animals resulted in profound neuro-
logical deficits compared with the animals without 
L-NAME administration. This observation suggests 
other forms of NOS—namely inducible NOS and/
or neuronal NOS—likely play an important role in 
SAH-induced neurological deficits. Additional ex-
periments would be required to discern the specific 
mechanisms, but several possibilities exist. Inhibition 
of inducible NOS and/or neuronal NOS could further 
exacerbate regional or even global nitric oxide levels 
such that SAH-induced microcirculatory vasocon-
striction is more pronounced leading to greater re-
ductions in cerebral blood flow.
Our study has several limitations. First, though 
the endovascular perforation mouse model used in 
our study is well characterized and mimics many of 
the features of SAH in humans, our findings will re-
quire validation in alternate animal models of SAH. 
Second, our study focused solely on vasospasm-in-
duced DCI and neurological deficits. Other contrib-
utors of DCI such as microcirculatory dysfunction 
have been described, and the impact of isoflurane 
conditioning on these non-vasospasm elements of 
DCI will require additional study. Third, the impact of 
isoflurane on longer-term end points such as neu-
robehavioral deficits after SAH were not evaluated, 
which will be important before considering transla-
tional studies in humans. Finally, the dose of isoflu-
rane used in our study is greater than that typically 
used in patients, so additional studies to define op-
timal isoflurane dosing as well as a therapeutic win-
dow will be required.
CONCLUSIONS
We conclude that isoflurane provides significant pro-
tection against SAH-induced vasospasm and neuro-
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of this robust neurovascular protection. Given that 
isoflurane is already approved by the Food and Drug 
Administration for use in humans and has an excel-
lent safety profile, the potential for translation to early 
phase clinical trials is imminently feasible. Future stud-
ies further exploring the molecular underpinnings of 
isoflurane conditioning-based neurovascular protec-
tion in experimental SAH are also warranted, with the 
hopes of identifying druggable targets to be leveraged 
into novel therapies.
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